Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
In PC-3 cells, DA 3003-2 (0.3-30 µM; 48 h) exhibits anti-proliferative action with an IC50 value of 5 µM[1]. In PC-3 cells, DA 3003-2 (5, 10 µM; 24, 1 h) enhances the expression of P-tyr15 Cdc2 and promotes cell cycle arrest in the G2/M phase [1].
|
---|---|
Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: PC-3 cells Tested Concentrations: 0.3-30 µM Incubation Duration: 48 h Experimental Results: demonstrated antiproliferative efficacy in a dose-dependent manner with an IC50 value of 5 µM. Cell Cycle Analysis[1] Cell Types: PC-3 cells Tested Concentrations: 5, 10 µM Incubation Duration: 24 h Experimental Results: Induced cell cycle arrest at G2/M phase. Western Blot Analysis[1] Cell Types: PC-3 cells Tested Concentrations: 5, 10 µM Incubation Duration: 1 h Experimental Results: Increased the expression of P-tyr15 Cdc2. |
References |
[1]. Nemoto K. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2). Exp Ther Med. 2010 Jul;1(4):647-650.
|
Molecular Formula |
C15H16CLN3O3
|
---|---|
Molecular Weight |
321.76
|
CAS # |
383907-47-9
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C1=CC2=C(C(=O)C(=C(C2=O)NCCN3CCOCC3)Cl)N=C1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 150 mg/mL (466.19 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (11.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1079 mL | 15.5395 mL | 31.0791 mL | |
5 mM | 0.6216 mL | 3.1079 mL | 6.2158 mL | |
10 mM | 0.3108 mL | 1.5540 mL | 3.1079 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.